Results 151 to 160 of about 53,776 (316)

Giant Lipoma of the Arm Masquerading as an Accessory Breast: A Report of a Rare Case. [PDF]

Cureus, 2023
Yadav AK, Sharma A, Meena RN.
europepmc   +1 more source

Correction to: Treatment with Ultrasound-Assisted Liposuction of Accessory Axillary Breast Tissues [PDF]

, 2022
İlteriş Murat Emsen
openalex   +1 more source

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

Advanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai   +6 more
wiley   +1 more source

Folic Acid‐Modified Ginger‐Derived Exosome‐Like Nanoparticles Co‐Delivering Sunitinib Suppress Renal Cell Carcinoma via PI3K‐Akt Pathway Inhibition, P‐gp Downregulation, and Macrophage Reprogramming

Advanced Science, EarlyView.
FPD‐GELNs co‐deliver Su and bioactive components. This active‐passive dual‐targeting strategy suppresses the progression of RCC through the following mechanisms: 1) inhibition of the PI3K‐Akt signaling pathway; 2) downregulation of ABCB1/P‐gp to enhance the chemosensitivity of RCC to Su; and 3) reprogramming of macrophages toward M1 polarization and ...
Haoyu Xu, Daixing Hu, Shixue Liu, Lei Yang, Junwu Li, Yuanyuan Bai, Guozhi Zhao, Wei Tang, Li Jiang   +8 more
wiley   +1 more source

A Case of Axillary Fibroadenoma That Grew Rapidly from Axillary Accessory Breast Tissue over 40 Days. [PDF]

Plast Reconstr Surg Glob Open, 2023
Ishiguro A, Tosa M, Sakatani T, Ohashi R, Ogawa R.   +4 more
europepmc   +1 more source

Targeting the Notch1‐YY1‐ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8+ T‐Cell‐Driven Cancer Cell Pyroptosis

Advanced Science, EarlyView.
In hepatocellular carcinoma (HCC), aberrantly activated Notch1 signaling induces its target gene YY1, which impairs immunotherapy efficacy by suppressing tumor cell‐ICAM1‐driven T cell activation and the mediated pyroptosis of T cells against tumor cells.
Ke Zhu, Fa‐Peng Zhang, Chao Qin, Zhi‐Xiao Song, Cai‐Ni Yang, Shu‐Sheng Lin, Xian‐Huan Yu, Wen‐Rui Wu, Chao‐Qun Liu, Chao Liu, Lei‐Bo Xu   +10 more
wiley   +1 more source

An extremely rare case of axillary accessory breast swelling with uncommon association of methicillin-resistant Staphylococcus aureus. [PDF]

Cytojournal, 2023
Gautam P, Singh A, Singh D, Shrivastava V, Singh M, Hada V, Gupta B.   +6 more
europepmc   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source

Axillary accessory breast cancer reconstructed by a thoracodorsal artery perforator flap: A case report. [PDF]

Medicine (Baltimore), 2023
Yumoto A, Otsuki Y, Nuri T, Higashino E, Kimura K, Iwamoto M, Ueda K.   +6 more
europepmc   +1 more source

A Modular Vaccine Platform Against SARS‐CoV‐2 Based on Self‐Assembled Protein Nanoparticles

Advanced Science, EarlyView.
A modular BP26 nanoparticle vaccine platform incorporating the SpyTag/SpyCatcher system enables high‐density, repetitive antigen display with post‐expression flexibility. Conjugation of the SARS‐CoV‐2 RBD to BP26 nanoparticles elicits strong humoral immunity and confers protection against viral challenge in vivo.
Seojung Lee, Yejin Jang, Yujin Kim, Yumi Shin, Ji‐Joon Song, Meehyein Kim, Sangyong Jon   +6 more
wiley   +1 more source